Rheumnow Podcast

EULAR 2024 Daily Recap - Days 1 & 2

Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey

Mechanistic Promise in RA Doesn’t Always Mean Actual Gain

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis

Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Voclosporin and Steroids in Lupus Nephritis

Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.

3 Big Lupus Themes from EULAR 2024

Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.

Does B Cell Depletion Matter?

Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.

Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib

Is Cannabis Safe? (6.7.2024)

Dr. Jack Cush reviews FDA approval, news and journal articles -- Its the week before EULAR 2024 in Vienna!!

ACR’s Run at Goliath (PCPs) (5.31.2024)

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APP's - what do you think?

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Don't You Know Who I am (5.17.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This weeks question - Can we prevent gout, ILD or psoriasis?

My Cancelled Lecture (5.11.2024)

In lieu of this weeks podcast, Dr. Jack Cush records his "Life Lessons (that keep changing) in Rheumatology Lecture. A lecture recently cancelled because some of this content was objectionable? (I dont think so!)

Roadblocks to reaching remission in lupus Sponsored by GSK US Medical Affairs

The 2023 EULAR recommendations for the management of lupus advocate for a treat-to-target approach, aiming for remission or low-level disease activity state.3 In this video, Dr. Michelle Petri summarizes the clinical criteria to attain these targets, and their association with reducing organ damage accrual.

Featured BSR Abstracts (5.3.2024)

Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.

SLE Faculty Panel Q&A - Featuring Drs. David Karp, Michelle Kahlenberg, and Andrea Fava; moderated by Dr. Jack Cush

Tuesday Night Rheumatology- Mastering SLE

Join us for session highlights from RheumNow Live 2024. This webinar will feature highlights from these lectures followed by live audience Q & A: Rethinking Pre-Clinical Disease in Lupus David Karp, MD Biology and Rx of Lupus Flares Michelle Kahlenberg, MD Current/Future Biomarkers in SLE Andrea Fava, MD

Current & Future Biomarkers in SLE - Dr. Andrea Fava

Rheum Chapter Notes (4.26.2024)

Spondyloarthritis Faculty Panel Q&A - featuring Drs. Eric Ruderman, Lihi Eder, and Lianne Gensler; moderated by Dr. Artie Kavanaugh

Tuesday Night Rheumatology- Spondyloarthritis Spectrum

Join us for session highlights from RheumNow Live 2023. This webinar will feature highlights from these lectures followed by live audience Q & A: Nonradiographic Axial Spondyloarthritis Eric Ruderman, MD Enthesitis in Spondyloarthritis Lihi Eder, MD Future Therapy of Axial Spondyloarthritis Lianne Gensler, MD

Nonradiographic Axial Spondyloarthritis - Dr. Eric Ruderman

Canary in a Coal Mine (4.19.2024)

Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogrens, ILD, Gout and Uveitis.

Vasculitis Faculty Panel Q&A - featuring Drs. Catherine Sims, Anisha Dua, and Philip Seo- moderated by Dr. Jack Cush

Tuesday Night Rheumatology- Vasculitis Mavens

Join us for session highlights from RheumNow Live 2024. This webinar will feature highlights from these lectures followed by live audience Q & A: Vasculitis & Pregnancy Catherine Sims, MD GPA Management in 2024 Anisha Dua, MD, MPH Treat to Target in Vasculitis Philip Seo, MD

GPA Management in 2024 - Dr. Anisha Dua

Burnout or Retire (4.12.2024)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Is it time to worry about burnout and those who are leaving healthcare?

PsA Faculty Panel Q&A - featuring Drs. Alexis Ogdie, April Armstrong, and Lihi Eder; moderated by Dr. Artie Kavanaugh